Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ELI LILLY AND COMPANY

(LLY)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
06/14/2021 06/15/2021 06/16/2021 06/17/2021 06/18/2021 Date
226.1(c) 223.52(c) 220.76(c) 222.21(c) 218.97 Last
2 720 733 2 188 900 2 548 827 1 891 008 1 818 736 Volume
+0.90% -1.14% -1.23% +0.66% -1.46% Change
More quotes
Financials (USD)
Sales 2021 27 273 M - -
Net income 2021 6 537 M - -
Net Debt 2021 11 213 M - -
P/E ratio 2021 30,5x
Yield 2021 1,50%
Sales 2022 27 840 M - -
Net income 2022 7 334 M - -
Net Debt 2022 9 561 M - -
P/E ratio 2022 27,0x
Yield 2022 1,66%
Capitalization 202 B 202 B -
EV / Sales 2021 7,82x
EV / Sales 2022 7,60x
Nbr of Employees 35 000
Free-Float 99,8%
More Financials
Company
Eli Lilly and Company is a drug manufacturing company. The Company discover, develop, manufacture, and market products in a human pharmaceutical product segment. The CompanyÔÇÖs products include Diabetes and other endocrinology products, including Baqsimi, Basaglar, Forteo, Humalog, Humatrope, Humulin, Jardiance, Trajenta and Trulicity. Its Immunology products include Olumiant and Taltz. Its Neuroscience products... 
Sector
Pharmaceuticals
Calendar
06/18 | 11:00amPresentation
More about the company
Ratings of Eli Lilly and Company
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about ELI LILLY AND COMPANY
06/16ALEMBIC PHARMACEUTICALSá : JV Gets US FDA Nod for Testosterone Topical Solution
MT
06/15ELI LILLY ANDá : JPMorgan Adjusts Price Target on Eli Lilly to $260 From $240, M..
MT
06/15ELI LILLY ANDá : to Compare Migraine Drugs Emgality, Nurtec ODT in Phase 4 Study
MT
06/15AstraZeneca antibody cocktail fails to prevent COVID-19 in large trial
RE
06/14ELI LILLY ANDá : Significant Insider Selling Continues at Eli Lilly (LLY)
MT
06/14ELI LILLY ANDá : Lilly to Participate in Guggenheim Biopharma Strategy Series
PR
06/14ELI LILLY ANDá : Bernstein Adjusts Price Target on Eli Lilly to $250 From $205, ..
MT
06/14ELI LILLY ANDá : Goldman Sachs Adjusts Eli Lilly's Price Target to $270 From $25..
MT
06/14Fiserv Appoints Wafaa Mamilli to Board of Directors
AQ
06/11ELI LILLY ANDá : Significant Insider Selling in Shares of Eli Lilly (LLY) Contin..
MT
06/11INSIDER TRENDS : Insider Sales Continue 90-Day Trend at Eli Lilly
MT
06/11ELI LILLY ANDá : Thinking about trading options or stock in Crispr Therapeutics,..
PR
06/11MARKET CHATTER : Eli Lilly Says Internal Inquiry Shows No Wrongdoings in Stateme..
MT
06/10INSIDER TRENDS : Insider Prolongs Selling Trend at Eli Lilly
MT
06/10MARKET CHATTER : Eli Lilly Reportedly Says Internal Inquiry Shows Company Did No..
MT
More news
News in other languages on ELI LILLY AND COMPANY
06/17ELI LILLYá : lance une initiative contre la migraine
06/07MÄRKTE USA/Wall Street startet uneinheitlich in die Woche
06/07Biogen s'envole après le feu vert de la FDA à son traitement contre la maladi..
06/07AKTIEN IM FOKUS : Alzheimermittel hilft Biogen auf Rekordhoch - Morphosys fest
06/03USAá : Dem al lavoro su disegno legge per ridurre prezzi farmaci
More news
Analyst Recommendations on ELI LILLY AND COMPANY
More recommendations
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | LLY | US5324571083 | MarketScreener
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 222,09 $
Last Close Price 222,21 $
Spread / Highest target 21,5%
Spread / Average Target -0,05%
Spread / Lowest Target -21,2%
EPS Revisions
Managers and Directors
NameTitle
David A. Ricks Chairman, President & Chief Executive Officer
Anat Ashkenazi Chief Financial Officer & Senior Vice President
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Daniel M. Skovronsky Chief Scientific Officer & Senior Vice President
Diogo Rau Senior VP, Chief Information & Digital Officer
Sector and Competitors
1st jan.Capitalization (M$)
ELI LILLY AND COMPANY31.61%201 995
JOHNSON & JOHNSON4.98%435 090
ROCHE HOLDING AG12.75%328 768
PFIZER, INC.7.25%220 997
NOVARTIS AG2.73%210 424
ABBVIE INC.7.23%202 939